This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Patent Trial and Appeal Board institutes review of Merck's US Patent No. 7,713,947

( September 22, 2023, 20:30 GMT | Official Statement) -- In assessing a petition for inter partes review of claims 36, 38, 39, and 41-46 of Merck Serono S.A.'s US patent No. 7,713,947, the Patent Trial and Appeal Board finds that generic drugmaker Hopewell Pharma Ventures Inc. is likely to prevail with regard to at least one challenged claim. The '947 patent relates to a regimen for treating certain forms of multiple sclerosis.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login